Azetukalner, a Kv7 potassium channel opener, reduced the frequency of focal onset seizures by a placebo-adjusted rate of 42.7 ...

X-TOLE2 met primary endpoint in both dose groups, including -53.2% median percent change (MPC) from baseline in monthly FOS frequency with 25 mg ...

Xenon Pharmaceuticals’ anti-seizure candidate has smashed a pivotal trial out of the park, lowering seizure rates by more ...

By Siddhi Mahatole March 9 (Reuters) - Xenon Pharmaceuticals said on Monday its experimental epilepsy drug met the main goal of showing a statistically significant reduction in focal onset seizures in ...

March 9 (Reuters) - Xenon Pharmaceuticals said on Monday its experimental epilepsy drug met the main goal of showing a statistically significant reduction in focal onset seizures in a late-stage trial ...

Xenon Pharmaceuticals released positive topline results from a phase three study of its azetukalner drug for focal onset seizures. The study met its primary endpoint for median percent change in ...

Researchers have discovered that mutations in the FOXJ3 gene act as a "master switch" failure, disrupting how the brain builds its layers and leading to FCD, a primary cause of drug-resistant epilepsy ...

Partnership leverages Tenacia’s expertise in central nervous system (CNS) drug development and commercialization to accelerate U.S. and global ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Among those deemed “treatment sensitive,” 69.4% ...